PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.099
https://www.valueinhealthjournal.com/article/S1098-3015(18)33399-0/fulltext
Title :
PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33399-0&doi=10.1016/j.jval.2018.09.099
First page :
Section Title :
Open access? :
No
Section Order :
400